4th Quarter - Report

TIBER CREEK GROUP for ASTELLAS PHARMA US, INC.

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517). Issues related to drug pricing.

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JONATHON JONES —
SEAN RICHARDSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1178 (114th), S. 1466 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.